Views:0 Author:Site Editor Publish Time: 2020-05-30 Origin:Site
Obesity has become a serious global medical and social problem. The incidence of overweight and obesity in China from 1992 to 2002 increased from 14.6% to 21.8% in accordance with WHO standards. Obesity in the 2006 has affected the health of more than 200 million of Chinese people, and it is expected that the obesity population will rise rapidly in the coming decades. Obesity is often a risk factor for diseases such as hyperlipidemia, type 2 diabetes, fatty liver, high blood pressure, cardiovascular disease, and cancer, and the number of deaths worldwide is about 3 million per annum. The drugs used in clinical medicine did not make significant progress compared to 10 years ago, due to the discovery of severe adverse reactions. In a considerable period of time, "Pipe shut up, step on the legs", eat less and more moving, or the best way to lose weight.
Currently approved by the FDA for long-term use of weight loss drugs only lipase inhibitor orlistat (ORLISTAT), as well as 2012 the newly marketed serotonin 2C receptor agonist chloride Kaslin (Lorcaserin) and compound weight loss drug qsymia (containing amphetamine and topiramate). 4 new drugs declared to FDA in 2010 were rejected for safety. Therefore, safety has become the biggest weight loss drug research and development of the greatest challenge, but also must overcome the difficulties.
At present, there are two types of slimming drugs in the market, the pancreatic lipase inhibitor and the appetite inhibitor acting on the central nervous system. Appetite inhibitors are limited because they can cause adverse reactions to the nervous system, and trypsin inhibitor Oliver he loses weight by inhibiting the activity of the pancreatic lipase, which inhibits the decomposition and absorption of fat in the food. But because it can cause fat diarrhea, can cause fat soluble vitamin deficiency. It has recently been reported that it can cause liver damage. Although central nervous system appetite inhibitors lorcaserin and qsymia have become the FDA's first approved weight-loss drug for 13 years, they still have security uncertainties in the brain's central and cardiovascular systems. There are only a handful of choices in the market for slimming drugs. If can appear the curative effect is good but the adverse reaction low the weight loss medicine, its market will obtain the remarkable expansion.
The difficulty of developing weight-loss drugs has led to few new drug listings over the years. Although Lorcaserin and Qsymia have been listed after years of research and development and repeated FDA audits, they still face the test of drug safety. At present, a variety of weight loss drugs are undergoing clinical trials or experimental research.